XML 32 R17.htm IDEA: XBRL DOCUMENT v3.25.0.1
SEGMENTS, GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA
 12 Months Ended
Dec. 31, 2024
Segment Reporting [Abstract]  
SEGMENTS, GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA
NOTE 11:-
SEGMENTS, GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA
 
ASC 280, “Segment Reporting,” establishes standards for reporting information about operating segments. Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker ("CODM") in deciding how to allocate resources and in assessing performance. The Company’s business is comprised of one operating segment.
 
The Company's CODM is its Chief Executive Officer (“CEO”), who reviews financial information presented on a consolidated basis.
 
The CODM uses consolidated net loss to assess financial performance and allocate resources. These financial metrics are used by the CODM to make key operating decisions, such as the allocation of budget between Research and development, Sales and Marketing, and General and Administrative expenses. Segment assets that are reviewed by the CODM is reported within the Consolidated Balance Sheet as consolidated total assets.
 
The following table presents selected financial information with respect to the Company’s single operating segment and includes information about segment revenues and significant segment expenses, for the years ended December 31, 2024, 2023 and 2022:
 
   
Year ended December 31,
  
   
2024
    
2023
    
2022
  
                   
Total Revenues
  
$
27,864
    
$
33,459
    
$
7,500
  
Less:
                        
          R&D expenses
                        
               Preclinical
    
15,374
      
20,948
      
17,477
  
               Clinical
    
15,267
      
10,627
      
11,357
  
           SG&A
    
9,485
      
9,320
      
9,690
  
           Financial income, net
    
(5,182
)
    
(3,215
)
    
(1,738
)
           Taxes on income
    
4,522
      
8,970
      
58
  
           Other segment expenses*
    
2,629
      
5,563
      
4,350
  
                         
Net loss
  
$
(14,231
)
  
$
(18,754
)
  
$
(33,694
)
 
*Other segment expense (income) during the years ended December 31, 2024, 2023 and 2022 includes property and equipment depreciation, participation in R&D expenses, share-based compensation and other adjustments.
 

Operations in Israel and the United States include research and development, clinical operations, general and administrative, marketing and business development. Total revenues are attributed to geographic areas based on the location of the end customer.

 
The following represents the total revenue for the years ended December 31, 2024, 2023 and 2022 and long-lived assets as of December 31, 2024 and 2023:
 
   
Year ended December 31,
  
   
2024
    
2023
    
2022
  
Revenue from sales to customers:
                  
                   
Europe
  
$
5,000
    
$
10,000
    
$
7,500
  
United States
    
22,864
      
23,459
      
-
  
                         
Total revenue
  
$
27,864
    
$
33,459
    
$
7,500
  
 
   

December 31,
   
2024
    
2023
  
Long-lived assets:
            
             
Israel
  
$
3,677
    
$
2,468
  
United States
    
18
      
77
  
                 
Total long-lived assets
  
$
3,695
    
$
2,545
  
 
   
Year ended December 31,
  
   
2024
    
2023
    
2022
  
Sales to a single customer exceeding 10%:
                  
                   
Customer A
    
18
%
    
30
%
    
100
%
Customer B
    
82
%
    
70
%
    
-